The Innovation Series: Reimbursement 101

Developing an understanding of the market access reimbursement landscape can be challenging for a startup with impactful new technology in the life sciences. For entrepreneurs to succeed in making a difference in human health, they need to go beyond inventing an efficacious treatment to designing a path forward that will lead to adoption of their technology, with pragmatic considerations at every step. Moving past efficacy alone, this forum explores how provider groups and payers use value in their analysis of what technologies to adopt.

As Verily is hosting across the street from CLSI, please allow 10 minutes to check in and make your way to the conference facility.

Program Agenda

5:00pm Registration Opens

5:30pm Opening Remarks | Lori Lindburg, President & CEO, CLSI

5:40pm Panel Discussion

6:40pm Audience Q&A

7:00pm Networking Reception

Panelists

John Hernandez, PhD, Head of Health Economics & Outcomes Research, Verily Life Sciences

Jennifer Kurkjian, Vice President, Managed Care, Dignity Health

Kelvin Lam, MD, Chief Medical Officer, Sutter Health Bay Area

Moderator

Jessica Holmes, Executive Director of Reimbursement, Argenta Advisors

Jessica has over 20 years of experience in payer relations, government affairs, and reimbursement strategy and tactical planning.

Jessica provides expertise in analyzing barriers and opportunities for market access in not only the traditional reimbursement environment of public and private health plans, but in the evolving value-based healthcare landscape (e.g., integrated networks, shared savings/ACOs and VBP/P4P programs).

She uses her bachelor’s degree in Mass Communication from the University of California at Berkeley and her work in public relations to cross-functionally align reimbursement goals with corporate sales and marketing initiatives.

Jessica earned a Master of Jurisprudence (MJ) in Health Law from Loyola University, Chicago, which she draws on for work in such areas as compliance, healthcare contracts, as well as legislative and regulatory analysis.

In Partnership With: